{"disease":{"id":"locally-advanced-urothelial-cancer","name":"locally advanced urothelial cancer"},"drugs":{"marketed":[{"drug_id":"chembl-chembl3301589","indication_name":"Locally Advanced or Metastatic Urothelial Cancer (Combination Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."},{"drug_id":"chembl-chembl3301589","indication_name":"Locally Advanced or Metastatic Urothelial Cancer (Single Agent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03682068","title":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1246,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03244384","title":"Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":739,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04527991","title":"Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03679767","title":"A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04004221","title":"Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT03682289","title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":89,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT06764095","title":"Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03237780","title":"Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03891238","title":"Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Consorzio Oncotech","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03590054","title":"Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT04940299","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03854474","title":"Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04963153","title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06630247","title":"A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT04953104","title":"ARID1A and/or KDM6A Mutation and CXCL13 Expression","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04848519","title":"Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT07217496","title":"N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Vadim S Koshkin","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}